Slingshot members are tracking this corporate initiative:
Novartis (NVS) Agrees to Exclusive Worldwide License Agreement for Contaus Pharma's (CNAT) Orally Active Pan-Caspase Inhibitor Emricasan
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Dec 19, 2016 Projected Implementation: Q1, 2017 Relevance Tracked Until: Q1, 2019
Don’t see a project related to the strategic initiative you care about?
Related Keywords Exclusive Worldwide License Agreement, Orally Active, Pan-caspase Inhibitor, Emricasan